MediciNova plans to initiate a clinical trial of MN 166 for COVID-19 Acute Respiratory Distress Syndrome (ARDS).
Related news and insights
Mallinckrodt Plc announced the publication of findings from a retrospective chart review study assessing the real-world use and outcomes of INOmax (nitric oxide) gas, for inhalation therapy in hospitalized patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome (ARDS), a disorder in which fluid leaks into the lungs, making breathing difficult or impossible.
Veru Inc. announced positive efficacy and safety results from a planned interim analysis of the double-blind, randomized, placebo-controlled Phase III COVID-19 clinical trial evaluating oral VERU 111 (sabizabulin) 9 mg versus placebo in 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS).
Veru Inc. announced that the Independent Data Monitoring Committee (IDMC) has conducted a planned conditional power analysis of the first 75 randomized patients in the Global Phase III COVID-19 registration study evaluating novel oral sabizabulin in hospitalized patients with moderate to severe COVID-19 infection who are at high risk for acute respiratory distress syndrome (ARDS) and death and has concluded the clinical study should continue as originally designed.